BiotechTube
Neurofix

Neurofix

Madrid, Spain· Est.
neurofixpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Neurofix Pharma is a private, clinical-stage biotech based in Madrid and Salamanca, Spain, developing small molecule therapeutics for neurological conditions. Its lead program, NFX88, is poised to enter final-phase clinical trials for spinal cord injury-related neuropathic pain, having cleared a Phase IIA study. The company is backed by a mix of public grants, institutional loans, and private investment, including from the Matutes family office, and is actively engaging with the European biotech community to advance its pipeline.

NeurologyPain

Opportunities

NFX88 addresses a high-unmet need in neuropathic pain from spinal cord injury, a condition with limited effective therapies.
Successful Phase III development could lead to a valuable commercial asset in a multi-billion dollar global pain market.
Strong institutional backing provides credibility and a foundation for attracting further investment or partnership deals.

Risk Factors

The company faces high clinical risk as its lead candidate must succeed in costly and complex Phase III trials.
Financial sustainability depends on raising significant capital in the absence of revenue.
Value is concentrated in a single asset, creating a binary outcome for the company.

Competitive Landscape

The neuropathic pain market is competitive, with existing generic drugs and newer branded agents, though many have limitations in efficacy or tolerability for SCI pain. Neurofix's NFX88, if successful, would need to differentiate itself on safety, efficacy, or mechanism of action. The company may also face competition from other biotechs developing novel neuromodulatory or analgesic therapies.

More companies in Spain →